BioSpace News Archive

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences.

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference and will present an overview of the company and provide a business update.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2023.

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) today reported financial results for the third quarter ended September 30, 2023 and withdrew its guidance for full year 2023.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the third quarter ended September 30, 2023.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today reported financial results for the quarter ended September 30, 2023.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the third quarter ended September 30, 2023, and provided updates on its ophthalmology pipeline.

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2023 and provided a corporate update.